Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 224-506-8 | CAS number: 4390-04-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Repeated Dose Oral 90d - NOAEL ≥ 500 mg/Kg bw/day for rats (OECD 408); BMDL = 1857 mg/Kg bw/day.
Repeated Dose Inhalation 90d – NOAEC ≥ 6000 mg/m3 for rats (similar to OECD TG 413)
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- a short-term toxicity study does not need to be conducted because a reliable sub-chronic (90 days) or chronic toxicity study is available, conducted with an appropriate species, dosage, solvent and route of administration
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- 1991
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Acceptable, well-documented study report equivalent or similar to OECD guideline 408: GLP
- Justification for type of information:
- A discussion and report on the read across strategy is given as an attachment in IUCLID Section 13.
- Reason / purpose for cross-reference:
- read-across: supporting information
- Qualifier:
- according to guideline
- Guideline:
- EPA OPP 82-1 (90-Day Oral Toxicity)
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Principles of method if other than guideline:
- According to EPA guideline 82-1
- GLP compliance:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Harlan Sprague Dawley Inc.
- Age at study initiation: ca. 6 weeks
- Weight at study initiation: 238-295g (males); 180-236g (females)
- Housing: individual
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum):ad libitum
- Acclimation period: 16 days
ENVIRONMENTAL CONDITIONS
- Temperature (°F): 68-76
- Humidity (%): 40-70
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: 1990-12-17 To: 1991-07-13 - Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
Test material was mixed with corn oil to ensure a 10ml/kg dose volume at all dose levels.
Test material mixtures were administered by oral gavage at a dose volume of 10ml/kg. The control animals received carrier at a dose of 10ml/kg. The satellite group was dosed at the high dose level for the same duration as main test and allowed to recover for 28 days post-treatment.
VEHICLE
- Amount of vehicle (if gavage): 10ml/kg - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Samples of test material in corn oil were analyzed by Gas Chromatography for concentration verification, stability and uniformity analysis. Concentration verification analysis showed the values to be within 5.6% of the target levels over a three month period. Samples of the 5% and 50% nominal concentration levels (500 and 5000 mg/kg/day, respectively) were kept under conditions of room temperature and refrigeration, prior to analyzing aliquots of these samples on days 0, 5 and 8. Sample aliquots were stable for up to 8 days under both conditions. To evaluate uniformity, triplicate aliquots of the 5% and 50% nominal concentration levels were analyzed. Mean values of triplicate aliquots were 5.25% ± 0.13 and 52.5% ± 0.51, respectively.
- Duration of treatment / exposure:
- 13 weeks
- Frequency of treatment:
- 7 days/week
- Dose / conc.:
- 0 mg/kg bw/day (actual dose received)
- Remarks:
- Group 1 (Control)
- Dose / conc.:
- 500 mg/kg bw/day (actual dose received)
- Remarks:
- Group 2 (Low Dose)
- Dose / conc.:
- 2 500 mg/kg bw/day (actual dose received)
- Remarks:
- Group 3 (Mid Dose)
- Dose / conc.:
- 5 000 mg/kg bw/day (actual dose received)
- Remarks:
- Group 4 (High Dose)
- Dose / conc.:
- 5 000 mg/kg bw/day (actual dose received)
- Remarks:
- Group 5 (Satellite Group)
- No. of animals per sex per dose:
- 10 animals/sex/dose
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Test material mixtures were administered by oral gavage at three different doses at a dose volume of 10ml/kg. The control animals received carrier at a dose of 10ml/kg. The satellite group was dosed at the high dose level for the same duration as the main test and allowed to recover for 28 days post-treatment.
- Post-exposure recovery period in satellite groups: 28 days post-treatment - Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily monday-friday and once daily on weekends and holidays
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: daily
BODY WEIGHT: Yes
- Time schedule for examinations: prior to dosing, the day of dose initiation, and weekly thereafter
OPHTHALMOSCOPIC EXAMINATION: Yes
at study initiation and during the final week of the main study
HAEMATOLOGY: Yes
- Time schedule for collection of blood: at main study termination and on satellite animals on the day of recovery sacrifice
- Anaesthetic used for blood collection: No
- Animals fasted: Yes
- How many animals:all
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: at main study termination and on satellite animals on the day of recovery sacrifice
- Animals fasted: Yes
- How many animals: all
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes - Statistics:
- The following parameters were statistically analyzed for significant differences: mean hematology parameters, serum chemistry parameters, organ weights, organ to body weight ratios, body weights, mean food consumption. Comparisons were limited to within sex analysis. Statistical evaluation of equality of means was done by an appropriate one way analysis of variance and a test of ordered response in the dose groups. First, Bartlett’s test was performed to determine if the dose groups have equal variance. If the variances were equal, the testing was done using parametric methods, otherwise nonparametric techniques were used.
For the parametric procedures, a standard one way ANOVA using the F distribution to assess significance was used. If significant differences among the means were indicated, Dunnett’s test was used to determine which treatment groups differ significantly from control. In addition to ANOVA, a standard regression analysis for liner response in the dose groups and linear lack of fit were preformed.
For the nonparametric procedure the test of equality of means was performed using the Kruskal-Wallis test. If significant differences among the means was indicated, Dunn’s Summed Rank test was used to determine which treatment group differ significantly from control. In addition, Jonckheere’s test for monotonic trend in the dose response was performed.
The statistical t-test was used to compare the satellite group’s main study termination and recovery termination hematology and clinical chemistry values. In addition, the t-test was used to compare the satellite group's and the control group's relative organ weights. The t-test was also used to compare the high dose and satellite groups to ensure similar results in order to accurately evaluate the recovery effects. - Clinical signs:
- effects observed, non-treatment-related
- Description (incidence and severity):
- The majority of animals in the control, low and mid-dose groups appeared normal. Very low sporadic incidences of scabs, alopecia, fur staining, dry/wet rales, dyspnea, dried red nasal discharge and hypoactivity were observed across all dose groups, but particularly in the high dose and satellite groups. The frequencies of these observations notably decreased over time during the satellite recovery period.
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- A total of fourteen unscheduled deaths were recorded across all dose groups for the duration of the study. With the exception of one 2500 mg/Kg female, for which the cause of death was not determined, all other unscheduled deaths were attributed to dosing trauma and/or incidental aspiration of test material based on post-mortem and histopathological findings. The animal deaths associated with the dosing procedures appeared to be related to physical characteristics of the test material and high dosage volume.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Statistically significant decrements in mean body weights were observed for mid dose males from week 11 and high dose males from week 8 (p≤ 0.05 and p ≤0.01 significance level, respectively). Body weights for male rats in the satellite group were similar to those in the high dose groups, although there was a trend towards recovery following main study termination. Statistically significant body weight differences in treated female rats were small (≤10% difference) and restricted to mid and high dose groups at week 13. Mean body weights for females in the satellite group were similar to controls, suggesting that slight changes observed in the mid and high dose groups were not toxicologically relevant.
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Statistically significant increases in food consumption which were linearly related to dose were noted for males on Days 28 through 56 and Day 70 through termination. Significance levels were noted for both the mid and high dose males during these periods. These trends were also evident in the females where statistically significant increases in food consumption were noted on Days 21, 42, 49, and 63 through 95.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Analysis of blood samples from rats at study termination showed a statistically significant, dose-dependent increase in platelet counts in all treated males and high dose females. In addition, red blood cell counts, hematocrit, hemoglobin, mean corpuscular volume and mean corpuscular hemoglobin were statistically significantly decreased in mid dose males compared to controls. Although the cause of these decreases could not be ascertained, the lack of similar effects in the high dose males suggested these changes were not treatment related. With the exception of the increased platelet counts, all other effects were reversed in recovery group rats.
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Examination of serum chemistry values revealed a statistically significant increase in blood urea nitrogen (BUN) and gamma glutamyl transferase (GGT) for high dose males and also mid dose males for BUN. Cholesterol levels were dose dependently increased relative to control in both males and females, with statistically significant increases occurring at the mid and high dose groups. Glucose values were significantly lower than the control values at the p ≤ 0.01 level for both males and females in the mid and high dose groups and for the male low dose group at the p ≤0.05 significance level. Statistically significant increases in alanine aminotransferase (ALT) levels of 2- and 2.4-fold were observed in mid and high dose males, respectively. In the females, the high dose group showed a slight but not statistically significant increase in GGT compared to controls. Also noted was a statistically significant increase in total bilirubin (TBIL) in the high dose groups for both sexes. With the exception of small decreases in chloride levels in mid and high dose females, no statistically significant changes were noted for serum levels of calcium, phosphate, sodium and potassium (data not shown). All changes reported as statistically significant at study termination showed evidence of recovery trends in satellite rats held for 28 days post last exposure.
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Statistically significant differences in mean kidney weights, compared to vehicle control rats were observed for all treated male rats. Liver weights for all treated female rats and low and mid dose males were statistically significantly increased relative to respective vehicle controls. Although liver weights for high dose males showed an increasing trend relative to controls, they were not significantly different from control values. Mean adrenal weights were also significantly increased for high dose males, including mid and high dose females. With respect to changes in organ/body weight ratios, relative kidney weights were statistically significantly increased for all treated male rats. Similar changes were also observed for mid and high dose rat livers and adrenal glands for high dose males.
Relative testes weights for high dose males were statistically significantly increased (p ≤0.05); however the difference was small and may have been related to the differences in body weights. In females, statistically significant differences in relative liver and adrenal weights were observed for mid and high dose groups. Similar to male rats, relative kidney weights were also statistically significantly increased for all treated female rats. No changes were observed in relative ovary weights. All changes showed trends towards almost complete recovery in high dose rats held without treatment for 28 days post last exposure. - Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Most frequently observed abnormalities include small and large intestine distension (mid and high dose groups); swollen anus (high dose groups), staining of the fur (mid and high dose groups).
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Treatment-related microscopic changes were observed in the kidneys of all treated male rats, livers of all treated male and female rats, and the stomach and/or anus of male and female rats in the mid and high dose groups. Microscopic evaluation of the stomach revealed a dose-dependent increase in the incidence and severity of thickening of the non-glandular mucosa due to hyperplasia and hyperkeratosis of the squamous epithelium. Edema and inflammatory cell infiltrations in the submucosa and focal necrosis of the superficial glandular mucosa were also noted, although at a lower incidence. These changes showed reversibility in the severity of the hyperplasia and hyperkeratosis of the mucosa.
Most rats in the high dose groups exhibited anal swelling with thickened skin and mucosa around the anus due to hyperplasia and hyperkeratosis. Areas of necrosis, neutrophilic inflammatory cell infiltrations and pustular formations in the superficial mucosa and epidermis of the anus and surrounding skin were also observed. All other microscopic changes were considered to have occurred spontaneously and to have been unrelated to treatment.
Microscopic examination of the kidneys of male rats showed changes that are typical of male rat-specific hydrocarbon nephropathy. Renal changes consisted of accumulations of hyaline droplets in the cytoplasm of the proximal convoluted tubules, dilatation and granular cast formations in the medullary tubules and increased basophilia of cortical tubules. Affected basophilic cortical tubules showed changes consistent with both degeneration and regeneration. The renal changes were observed only in male rats, and there were no differences in the incidence and/or severity of
the lesions across treatment groups. Microscopic examination of the kidneys in the satellite group male rats necropsied after the 28-day recovery period showed no evidence of hyaline droplets in the cortical tubules. However, there was a 50% incidence of dilated tubules with granular casts in the medulla and a 30% incidence of focal chronic nephritis in rats in the recovery group. There was no difference in the incidence of cortical basophilic tubules between the control and recovery group male rats, indicating that the renal changes were reversible with discontinuation of exposure to test material.
Treatment-related effects in the liver consisted of hepatocellular hypertrophy, predominantly in centrilobular areas. The incidence and severity of hepatocellular hypertrophy was dose-related, consistent with the increased liver weights seen in all treated rats irrespective of sex. The liver lesions were completely absent in recovery rats. - Histopathological findings: neoplastic:
- not examined
- Details on results:
- CLINICAL SIGNS AND MORTALITY
One male and 1 female died in the control group, 2 females died in the 2500 mg/kg dose group, 4 females died in the 5000 mg/kg dose group, 2 males and 3 females died in the satellite group. With the exception of one 2500 mg/kg female, all of the other 13 listed spontaneous deaths appear to be a result of dosing trauma and/or aspiration of test material (due to physical characteristics of test material and the high dosage volume).
The majority of animals in the control, low and mid dose groups displayed no observable abnormal clinical signs. Observations included but are not limited to scabs, maloccluded incisors, alopecia and staining of fur, dry/wet rales, dyspnea, nasal discharge. The type and incidence of abnormal clinical signs were similar between the high dose and satellite groups with a dramatic increase in incidence when compared to mid dose group. Clinical signs most frequently noted included swollen anus, ano-genital staining, emaciation, and alopecia. During the satellite recovery period, the incidence of abnormal signs decreased over time with an increase in the number of animals exhibiting no observable abnormalities.
BODY WEIGHT AND WEIGHT GAIN
Statistically significant decreases from controls at the p<=0.05 level of significance were noted for mid dose males on days 77, 84, 91 and termination and for the high dose males on Day 42. A statistically significant decrease (p<=0.01) was noted for the high dose group males on Day 49 and continued through the end of the treatment period. Statistically significant decreases were noted for mid dose females (p<=0.05) on day 91 and for high dose females on days 77 and 91. At termination both mid and high dose females displayed a statistically significant decrease in body weight.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study)
Statistically significant increases in food consumption which were linearly related to dose were noted for males on Days 28 through 56 and Day 70 through termination. Significance levels were noted for both the mid and high dose males during these periods. These trends were also evident in the females where statistically significant increases in food consumption were noted on Days 21, 42, 49, and 63 through 95.
OPHTHALMOSCOPIC EXAMINATION
No treatment-related findings.
HAEMATOLOGY
A statistically significant increase in platelets which was linearly related to dose in both the males and females was observed. In addition the male animals displayed a linear dose related increase in white blood cells. The mid dose male values were noted to differ significantly from those of controls for hematocrit and hemoglobin at the p<=0.01 level of significance and mean corpuscular volume and mean corpuscular hemoglobin at the p<=0.05 level of significance.
CLINICAL CHEMISTRY
Statistically significant increases in males (p<=0.01) for urea nitrogen and gamma glutamyl transpeptidase for the high dose males and also the mid dose males for urea nitrogen. An increase for cholesterol was noted for the mid and high dose groups of both sexes (p<=0.01). An increase in alanine aminotransferase was also noted for the mid and high dose males (p<=0.01). Glucose levels were significantly lower than the control values (p<=0.01) for both sexes in the mid and high dose and for the male low dose (P<=0.05). A statistically significant increase in bilirubin in the high dose of both sexes was observed. Other parameters showing statistically significant differences from controls included creatinine, chloride, tryglycerides.
ORGAN WEIGHTS
Liver weights were elevated in male and female rats at 2500 and 5000 mg/kg/day. Adrenal weights were significantly increased in male and female rats at 5000 mg/kg and in female rats at 2500 and 5000 mg/kg. Testes weights were elevated in male rats at 5000 mg/kg. Both the male and female relative kidney weights for all treated groups were significantly different from the control value (p<=0.01).
GROSS PATHOLOGY
Most frequently observed abnormalities include small and large intestine distension (mid and high dose groups); swollen anus (high dose groups), staining of the fur (mid and high dose groups). - Key result
- Dose descriptor:
- other: BMDL
- Effect level:
- 1 857 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Systemic Toxicity
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 500 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Systemic Toxicity
- Key result
- Critical effects observed:
- no
- Conclusions:
- Based on a significant increase in ALT levels in the 2500 and 5000 mg/kg/day treatment groups in male rats, the No Observed Adverse Effect Level (NOAEL) for the 90-day study was greater than 500 mg/Kg/day.
This NOAEL value is dependent on doses selected in the study and may not represent a true biological threshold. In order to circumvent the problem of dose-selection bias, benchmark analysis was used to determine a benchmark dose for this study, using individual ALT dose–response values in male rats as the critical effect. Since the minimal level of change in the endpoint (increased serum ALT) that would be considered biologically significant was known (2–4-fold increase compared to concurrent control values), this value was used as the Benchmark response in the derivation of a BMDL, although the BMDL value using the EPA default BMR of 1SD from the mean was provided for comparison. The use of the 1SD default for the BMR resulted in an overly conservative BMDL value, 3-fold lower than would have been predicted using the NOAEL/ LOAEL approach. When the BMR was more accurately defined in terms of a 2-fold minimum level of change over the control mean, the estimated BMDL value was 1857 mg/Kg. - Executive summary:
MRD-89-582 was administered by oral gavage to rats at concentrations of 500, 2500 and 5000 mg/kg, 7 days a week for 13 weeks to assess the subchronic toxicity. An additional group of animals, dosed at 5000 mg/kg/day, was held for 4 weeks to assess reversibility. No treatment-related mortality was observed; however, male body weights were decreased while food consumption increased in the 2500 and 5000 mg/kg dose groups. Liver weights were elevated in male and female rats at 2500 and 5000 mg/kg/day. Adrenal weights were significantly increased in male and female rats at 5000 mg/kg and in female rats at 2500 and 5000 mg/kg. Testes weights were elevated in male rats at 5000 mg/kg. Kidney effects occurred in males at all dose levels, and are indicative of alpha-2u-globulin nephropathy. Alpha-2u-globulin nephropathy, also known as hyaline droplet nephropathy, results from the formation of complexes with a naturally occurring protein (alpha-2u-globulin) in the kidneys of male rats. These complexes can accumulate in the proximal renal tubule and may produce species-specific histopathological changes. These kidney effects are specific to male rats and are not considered to be of biological relevance to humans.
Dose-related changes in hematology or serum chemistry parameters were observed and were consistent with the changes seen in the liver. Histological findings of hepatocellular hypertrophy (liver cell enlargement) were seen in livers of both sexes in all dose groups. These findings are believed to have been a compensatory response and not an indication of toxicity. Additionally, these liver effects were reversible and occurred only at high doses that are not typical of hydrocarbon exposures for humans. Other treatment-related effects were mucosal thickening and other signs of irritation of the stomach and anus which appear to be the direct result of high dose intubation of a the locally irritating test substance. These effects are believed to have been a compensatory response to local irritation and not an indication of toxicity. All treatment-related effects were reversible within the 4-week recovery period. Based on a significant increase in ALT levels in the 2500 and 5000 mg/kg/day treatment groups in male rats, the No Observed Adverse Effect Level (NOAEL) for the 90-day study was greater than 500 mg/Kg/day.
This NOAEL value is dependent on doses selected in the study and may not represent a true biological threshold. In order to circumvent the problem of dose-selection bias, benchmark analysis was used to determine a benchmark dose for this study, using individual ALT dose–response values in male rats as the critical effect. Since the minimal level of change in the endpoint (increased serum ALT) that would be considered biologically significant was known (2–4-fold increase compared to concurrent control values), this value was used as the Benchmark response in the derivation of a BMDL, although the BMDL value using the EPA default BMR of 1SD from the mean was provided
for comparison. The use of the 1SD default for the BMR resulted in an overly conservative BMDL value, 3-fold lower than would have been predicted using the NOAEL/ LOAEL approach. When the BMR was more accurately defined in terms of a 2-fold minimum level of change over the control mean, the estimated BMDL value was 1857 mg/Kg/day.
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- 1991
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: According to or similar to OECD guideline 408: GLP
- Justification for type of information:
- A discussion and report on the read across strategy is given as an attachment in IUCLID Section 13.
- Reason / purpose for cross-reference:
- read-across: supporting information
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- GLP compliance:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Harlan Sprague Dawley Inc.
- Age at study initiation: Approximately 6 weeks
- Weight at study initiation: Males: 156.2-223.2 g; Females: 136.2-170.9 g
- Housing: Individually
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: 16 days
ENVIRONMENTAL CONDITIONS
- Temperature (°F): maintained range of 68-76
- Humidity (%): maintained range of 40-70
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: October 24, 1990 To: September 27, 1991 - Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
The test material was diluted in vehicle at the following concentration to ensure a 5ml/kg dose volume at all dose levels:
-Group 2=0.1g/kg (2.0% w/v)
-Group 3= 0.5g/kg (10% w/v)
-Group 4 and 5= 1.0g/kg (20.0% w/v)
VEHICLE
- Amount of vehicle (if gavage): 5ml/kg - Duration of treatment / exposure:
- 13 weeks
- Frequency of treatment:
- The test material mixtures and control were administered by oral gavage at a dose volume of 5ml/kg, 7 days per week for a period of 13 weeks.
- Remarks:
- Doses / Concentrations:
0.1g/kg (2.0w/v)
Basis:
actual ingested - Remarks:
- Doses / Concentrations:
0.5g/kg 10% w/v)
Basis:
actual ingested - Remarks:
- Doses / Concentrations:
1.0g/kg (20% w/v)
Basis:
actual ingested - No. of animals per sex per dose:
- All groups consisted of 20 mice (10males; 10 females)
Group 1=Control group (
Group 2= 0.1g/kg (2.0% w/v)
Group 3= 0.5g/kg (10% w/v)
Groups 4=1.0g/kg (20% w/v).
Group 5 (satellite)= 1.0g/kg (20% w/v). - Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Rationale for selecting satellite groups: observed for reversibility, persistence or delayed occurrence of toxic effects
- Post-exposure recovery period in satellite groups: 28 days - Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Clinical observations were made daily. Clinical laboratory studies were performed on all animals pre-dose, interim (day 32 for males, and day 33 for females), and at main study termination. For the satellite animals, clinical laboratory studies were also performed on the day of recovery sacrifice.
BODY WEIGHT: Yes
- Time schedule for examinations: prior to dosing (pretest), on the day of dose initiation (Day 0), and weekly thereafter. Body weights were also recorded at sacrifice or death.
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: Prior to study initation and during the final week of the main study
- Dose groups that were examined: all dose groups
HAEMATOLOGY: Yes
- Time schedule for collection of blood: pre-dose, interim (day 32 for males, and day 33 for females), and at main study termination. Also on day of recovery sacrifice for the satellite animals.
- Anaesthetic used for blood collection: Yes-methoxyflurane
- Animals fasted: yes
- How many animals: all animals
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: pre-dose, interim (day 32 for males, and day 33 for females), and at main study termination. Also on day of recovery sacrifice for the satellite animals.
- Animals fasted: yes
- How many animals: all animals
URINALYSIS: No data
NEUROBEHAVIOURAL EXAMINATION: No data - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
The necropsy included an examination of the external surface of the body, all orifices, and the cranial, thoracic, and abdominal cavities and their contents. The kidneys, liver, ovaries, tested, adrenals, and brain were weighed prior to fixation.
HISTOPATHOLOGY: Yes
-erythrocyte count
-hematocrit
-hemoglobin
-leukocyte count
-mean corpuscular volume
-mean corpuscular hemoglobulin
-mean corpuscular hemoglobulin concentration
-platelets
-reticulocyte count
SERUM CHEMISTRY:
-total bilirubin
-albumin
-blood urea nitrogen
-calcium
-cholesterol
-creatinine
-electrolytes
-glucose
-total protein
-triglycerides
-phosphorous
-gamma glutamyl transferase
-serum aspartate aminotransferase
-serum alanine aminotransferase - Statistics:
- The following parameters were statistically analyzed for significant differences:
-mean hematology parameters
-mean serum chemistry parameters
- mean organ weights
- mean organ to body weight ratios
- mean body weights
- mean food consumption.
Comparisons were limited to within sex analysis.
Statistical evaluation of equality of means was done by an appropriate one way analysis of variance and a test for ordered response in the dose groups. Bartlett's test was performed first. If the dose groups had equal variance, a parametric method was used. Otherwise, nonparametric techniques were used.
Parametric procedures involved a standard one way ANOVA using the F distribution. If significant differences among the means were indicated, Dunnett’s test was used to determine significant differences from control. In addition, a standard regression analysis for linear response in the dose groups and linear lack of fit were performed.
Nonparametric procedures involved the test of equality of means using the Kruskal-Wallis test. If significant differences were indicated, Dunn’s Summed Rank test was used. In addition, Jonckheere’s test for monotonic trend in the dose response was performed.
The statistical t-test was used to compare the satellite group’s main study termination and recovery termination values. In addition, the t-test was used to compare the satellite group’s and the high dose group's relative organ weights. The t-test was also used to evaluate recovery. - Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- effects observed, treatment-related
- Clinical biochemistry findings:
- effects observed, treatment-related
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- HISTOPATHOLOGY: NON-NEOPLASTIC
Microscopic changes were observed in the kidneys and liver of male rats and in the livers of female rats. The treatment-related effects in the kidney were characterized predominantly by accumulations of hyaline droplets in the cytoplasm of the proximal tubules of the cortex. An increased incidence of multifocal cortical tubular basophilia with changes consistent with both degeneration and regeneration of the tubular epithelium also was present as well as dilated medullary tubules with granular casts. These renal changes were observed only in males in all doses necropsied immediately after the 90-day treatment period. The incidence and severity of these changes generally occurred in a dose-related manner. After the reversibility period, there were still residual changes but of a lesser degree. Dilated tubules with granular casts in the medulla and an increased incidence of multifocal cortical tubular basophilia were noted. No-treatment related microscopic changes were observed in the kidneys of the female rats.
Changes in the liver consisted of a minimal to slight centrilobular hepatocellular hypertrophy in the high dose male rats and in the female rats of the mid and high dose groups. The centrilobular areas were more prominent and the hepatocytes were larger with an increased amount of eosinophilic cytoplasm. Centrilobular hepatocellular hypertrophy was not observed in any of the satellite group rats.
OTHER FINDINGS
Two control female rats died prior to study termination. One rat had diffuse fibrinopurulent pleuropneumonia and pericarditis. These changes are believed to be related to a dosing accident with perforation of the esophagus in the thoracic cavity. The cause of death in the second control female included bacterial nephritis and an associated mucosal hyperplasia and distention of the ureter and urinary bladder. - Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 1 000 mg/kg bw/day (actual dose received)
- Sex:
- male/female
- Basis for effect level:
- other: No treatment-related clinical in-life signs of toxicity and no mortality were observed at the highest dose tested.
- Critical effects observed:
- not specified
- Conclusions:
- Oral administration via gavage for 90 days produced no treatment-related clinical in-life signs of toxicity and no mortality at the highest dose tested. The no observable adverse effect level for MRD-90-868 is > 1000 mg/kg.
- Executive summary:
A 90-day subchronic study was conducted in rats to assess the toxicity of MRD-90-868. The test mixture was administered by oral gavage at a dose of 0, 100, 500, or 1000 mg/ kg 7 days per week for a period of 13 weeks. The control animals received a carrier (corn oil) dose and a satellite group was dosed at 1000 mg/ kg, 7 days/week for 13 weeks and was then observed for reversibility, persistence or delayed occurrence of toxic effects for 28 days post-treatment. Observations were made as to the nature, onset, severity, and duration of toxicological signs. There were no deaths attributed to the oral administration of MRD-90-868 (two control group females died prior to termination). The majority of animals in all groups displayed no observable abnormalities during the test period. The most frequently noted observations included broken/maloccluded incisors, alopecia, and scabs, all of which were considered incidental. Body weight, food consumption, and hematology data displayed no biologically significant trends for either males or females during the test period. The most remarkable finding was a treatment-related microscopic change in the liver of the mid-dose females and the high dose of both sexes. This change was minor and is typical of an adaptive change probably related to the livers metabolism of large volumes of test material and was reversible upon microscopic evaluation of the tissues from the satellite recovery group. Microscopic changes were also observed in the male kidneys at all doses. These changes are characteristic of kidney changes produced in male rats by hydrocarbons and are considered to be a male rat specific phenomenon without human significance. Based on the data recorded in this study, the NOAEL for MRD-90 -868 is >1000mg/kg.
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study planned
- Study period:
- Will be completed in the timescale as indicated in the ECHA decision letter.
- Justification for type of information:
- This testing proposal has been presented in the lead registrant dossier for this substance submitted to ECHA in 2019. This is a source dossier where the overall approach should be seen in the context of a category of 108 different substances, where the substances are hydrocarbon solvents covering a carbon number range of C5-C20, based on alkane constituents and a range from approximately C8-C18 for aromatic constituents. The basis for this test proposal is set out in detail in the document ‘Hydrocarbon Solvents Test Proposals, Test Plans and Read-Across Strategy for Human Health Endpoints’, which is attached to this endpoint study record and in Section 13.2 of the IUCLID dossier.
TESTING PROPOSAL ON VERTEBRATE ANIMALS
[Please provide information for all of the points below. The information should be specific to the endpoint for which testing is proposed. Note that for testing proposals addressing testing on vertebrate animals under the REACH Regulation this document will be published on the ECHA website along with the third party consultation on the testing proposal(s).]
NON-CONFIDENTIAL NAME OF SUBSTANCE:
- Name of the substance on which testing is proposed to be carried out : Isohexadecane 2,2,4,4,6,8,8-heptamethylnonane (EC# 224-506-8)
- Name of the substance for which the testing proposal will be used [if different from tested substance] : Not different
CONSIDERATIONS THAT THE GENERAL ADAPTATION POSSIBILITIES OF ANNEX XI OF THE REACH REGULATION ARE NOT ADEQUATE TO GENERATE THE NECESSARY INFORMATION [please address all points below]:
- Available GLP studies : There are no OECD Guideline 408 studies available on this substance to evaluate the sub-chronic toxicity endpoint. These data only exist for structural analogues.
- Available non-GLP studies : There are no ‘non-GLP’ studies available for this substance to evaluate the sub-chronic toxicity endpoint. These data only exist for for structural analogues.
- Historical human data: No human data exist for this substance to evaluate sub-chronic toxicity hazard.
- (Q)SAR : There are no recognised (Q)SAR methods available for reliable prediction of sub-chronic toxicity.
- In vitro methods : There are no in vitro methods currently accepted by Regulatory Authorities for the reliable prediction of sub-chronic toxicity.
- Weight of evidence : Currently there are insufficient data available to develop a robust weight of evidence approach for the sub-chronic toxicity.
- Grouping and read-across : This test proposal maybe used to help develop a category approach for a wider range of hydrocarbons.
- Substance-tailored exposure driven testing [if applicable] : Insufficient data available
- Approaches in addition to above [if applicable]: None applicable
- Other reasons [if applicable]: None identified
According to the adaption principles of Annex XI of the REACH Regulation, there are no existing sub-chronic toxicity data (mammalian and human) for this substance, or for similar compositions, which could subsequently be used for read-across. Consequently, a weight of evidence approach is not sufficient to address this endpoint.
Both in-vitro and in-silico approaches are not considered to be appropriate, as there are no suitable methods which are considered to be valid and reliable to address the requirements for the Sub-Chronic Toxicity (90-Days) toxicity endpoint.
CONSIDERATIONS THAT THE SPECIFIC ADAPTATION POSSIBILITIES OF ANNEXES VI TO X (AND COLUMN 2 THEREOF) OF THE REACH REGULATION ARE NOT ADEQUATE TO GENERATE THE NECESSARY INFORMATION:
- There are no short-term toxicity studies (28-days) on this substance
- There are no chronic toxicity studies on this substance
FURTHER INFORMATION ON TESTING PROPOSAL IN ADDITION TO INFORMATION PROVIDED IN THE MATERIALS AND METHODS SECTION:
- Details on study design / methodology proposed [if relevant]: See 'Materials and Methods' Section for further information. - Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- GLP compliance:
- yes (incl. QA statement)
- Species:
- rat
- Sex:
- male/female
- Route of administration:
- oral: unspecified
Referenceopen allclose all
Table 2. Mean Hematology Values after a 90 day oral gavage study of C10-C13 dearomatised hydrocarbons solvent
Parameter |
Exposure dose (mg/kg/day) |
||||
0 (control) |
500 |
2500 |
5000 |
5000 (Recovery)a |
|
Males |
N=8 |
N=10 |
N=10 |
N=10 |
N=8 |
WBC (×103/mm3) |
7.6±2.7 |
9.2±2.3 |
10.4±2.8 |
10.8±2.3 |
7.7±1.7 |
RBC (×106/mm3) |
8.72±0.27 |
8.66±0.36 |
8.53±0.34 |
8.78±0.21 |
8.48±0.29 |
HGB (g/dl) |
15.6±0.6 |
15.2±0.4 |
14.6±0.6 ** |
15.2±0.5 |
15.6±0.5 |
HCT (%) |
45.0±1.3 |
44.0±1.3 |
41.9±1.8 ** |
44.0±1.7 |
43.0±1.3 |
MCV (fL) |
52.0±2.0 |
51.0±2.0 |
49.0±1.0 * |
50.0±2.0 |
51±1 |
MCH (pg) |
17.9±0.7 |
17.6±0.5 |
17.1±0.5 * |
17.4±0.6 |
18.4±0.5 |
MCHC (g/dl) |
34.7±0.4 |
34.6±0.4 |
34.9±0.4 * |
34.6±0.4 |
36.2±0.7 |
PLT (×103/mm3) |
770±40 |
877±45 * |
1008±73 ** |
984±115 ** |
1050±96 |
Females |
N=8 |
N=10 |
N=8 |
N=10 |
N=3 |
WBC (×103/mm3) |
5.4±2.5 |
4.4±1.0 |
4.2±0.8 |
6.8±1.6 |
5.1±1.9 |
RBC (×106/mm3) |
7.43±0.32 |
7.35±0.31 |
7.21±0.57 |
7.72±0.44 |
8.16±0.12 |
HGB (g/dl) |
14.1±0.6 |
14.1±0.4 |
13.5±1.2 |
14.5±0.7 |
15.4±0.3 |
HCT (%) |
39.6±1.5 |
40.0±1.2 |
38.0±3.4 |
40.8±1.9 |
42.8±0.9 |
MCV (fL) |
53.0±1.0 |
54.0±1.0 |
53.0±2.0 |
53.0±1.0 |
53±2 |
MCH (pg) |
19.0±0.5 |
19.2±0.6 |
18.7±0.7 |
18.8±0.4 |
18.9±0.4 |
MCHC (g/dl) |
35.6±0.3 |
35.2±0.5 |
35.5±0.3 |
35.6±0.4 |
36.0±0.3 |
PLT (×103/mm3) |
792±116 |
846±81 |
892±89 |
1023±110 ** |
1052±154 |
WBC – white blood cell
RBC – red blood cell
HGB – hemoglobin
HCT – hematocrit
MCV – mean cell volume
MCH – mean corpuscular hemoglobin
MCHC – mean corpuscular hemoglobin concentration,
PLT – platelet count
a Measurements on day 125, 2 of 10 and 2 of 6 rats excluded (due to death) in males and females, respectively
* P ≤0.05
** P≤0.01
Table3. Mean Clinical Chemistry values after a 90 day oral gavage study of C10-C13 dearomatised hydrocarbon solvent
Parameter |
Exposure dose (mg/kg/day) |
||||
0 (control) |
500 |
2500 |
5000 |
5000 (Recovery)a |
|
Males |
N=8 |
N=10 |
N=10 |
N=10 |
N=8 |
GGT (lU/L) |
1.80.18±0.83 |
1.60±0.97 |
2.90±0.99 |
4.90±1.91 ** |
0.88±0.83 |
Albumin (g/l) |
4.2±0.1 |
4.2±0.1 |
4.1±0.2 |
4.1±0.1 |
3.9±0.2 |
Glucose (mg/dl) |
128.6±11.3 |
113.8±10.5 * |
94.9±12.5 ** |
93.8±12.6 ** |
117.5±13.8 |
Chol (mg/dl) |
39.3±3.8 |
46.8±8.8 |
65.0±14.6 ** |
66.8±15.0 ** |
35.5±4.4 |
TBIL (mg/dl) |
0.49±0.04 |
0.48±0.06 |
0.62±0.15 |
0.61±0.12 * |
0.48±0.07 |
BUN (mg/dl) |
9.8±1.5 |
10.4±1.3 |
13.3±3.4 ** |
14.5±2.4 ** |
18.8±2.5 |
ALT (IU/il) |
37.5±3.9 |
42.5±8.0 |
75.0±18.3 ** |
90.7±26.0 ** |
31.8±6.2 |
AST IU/l) |
94.8±18.4 |
88.0±15.2 |
91.7±18.3 |
106.0±10.0 |
119.4±19.4 |
Crea (mg/dl) |
0.5±0.1 |
0.6±0.1 |
0.6±0.1 |
0.6±0.1 |
0.5±0.1 |
Females |
N=9 |
N=10 |
N=8 |
N=10 |
N=3 |
GGT (lU/L) |
1.0±0.87 |
0.60±0.70 |
1.38±0.92 |
1.90±1.60 |
2.33±1.15 |
Albumin (g/l) |
4.6±0.3 |
4.8±0.3 |
5.0±0.2 |
4.8±0.4 |
4.3±0.1 |
Glucose (mg/dl) |
107.2±6.4 |
104.0±13.6 |
89.5±9.7 ** |
81.4±6.8 ** |
118.0±18.7 |
Chol (mg/dl) |
48.3±8.4 |
63.6±9.8 |
95.0±18.2 ** |
81.9±16.1 ** |
66.3±17.2 |
TBIL (mg/dl) |
0.54±0.07 |
0.58±0.08 |
0.63±0.07 |
0.68±0.15 * |
0.50±0.10 |
BUN (mg/dl) |
12.8±2.6 |
12.2±1.9 |
11.6±1.8 |
13.2±1.9 |
17.7±0.6 |
ALT (IU/il) |
60.7±48.2 |
38.0±39.5 |
51.5±22.4 |
69.3±16.0 |
26.7±5.5 |
AST IU/l) |
113.9±49.0 |
93.6±38.3 |
97.3±13.6 |
115.9±13.9 |
88.7±23.7 |
Crea (mg/dl) |
0.6±0.1 |
0.7±0.1 * |
0.6±0.1 |
0.7±0.1 |
0.6±0.1 |
TBIL – total bilirubin
ALT – alanine amino transferase
AST – aspartate amino transferase
Chol – cholesterol
BUN – blood urea nitrogen
GGT – gamma glutamyl transferase
Crea – creatinine
a Measurements on day 125, 2 of 10 and 3 of 6 rats excluded (due to death) in males and females, respectively
* P ≤0.05
** P≤0.01
Table 4. Mean Absolute and Relative Organ Weights after a 90 day oral gavage study of C10-C13 dearomatised hydrocarbon solvent
Parameter |
Exposure dose (mg/kg/day) |
||||
0 (control) |
500 |
2500 |
5000 |
5000 (Recovery)a |
|
Males |
N=8 |
N=10 |
N=10 |
N=10 |
N=8 |
Mean absolute (g) |
|||||
Kidney |
3.32±0.46 |
4.43±0.58 ** |
4.38±0.57 ** |
4.11±0.40 ** |
3.48±0.32 |
Liver |
14.69±2.93 |
18.50±2.51 * |
19.85±2.98 ** |
18.01±2.90 |
12.18±1.52 |
Adrenals |
0.048±0.008 |
0.048±0.009 |
0.061±0.009 |
0.078±0.15 ** |
0.055±0.013 |
Testes |
3.8519±0.3234 |
3.7200±0.3770 |
3.4243±0.7249 |
3.5136±0.3797 |
3.7671±0.2455 |
Mean relative (g) |
|||||
Kidney |
0.0063±0.0005 |
0.008±0.0011 ** |
0.01±0.0007 ** |
0.0102±0.0015 ** |
0.0078±0.0006 |
Liver |
0..028±0.0001 |
0.033±0.001 |
0.045±0.004 ** |
0.044±0.004 ** |
0.027±0.001 |
Adrenals |
0.0001±0.00001 |
0.00009±0.00001 |
0.00014±0.00001 |
0.0019±0.00003 ** |
0.00012±0.00002 |
Testes |
0.0074±0.001 |
0.0067±0.0008 |
0.0078±0.0017 |
0.0087±0.0004 * |
0.0084±0.0011 |
Females |
N=9 |
N=10 |
N=8 |
N=10 |
N=3 |
Mean absolute (g) |
|||||
Kidney |
2.18±0.28 |
2.40±0.17 |
2.34±0.18 |
2.42±0.27 |
2.41±0.23 |
Liver |
8.57±1.12 |
10.33±0.89 * |
14.71±1.51 ** |
13.80±2.19 ** |
8.85±0.71 |
Adrenals |
0.067±0.019 |
0.074±0.010 |
0.094±0.010 ** |
0.102±0.012 ** |
0.075±0.007 |
Testes |
0.081±0.020 |
0.082±0.033 |
0.067±0.024 |
0.072±0.033 |
0.077±0.025 |
Mean relative (g) |
|||||
Kidney |
0.0072±0.0007 |
0.0084±0.0006 ** |
0.0089±0.0007 ** |
0.0091±0.0008 ** |
0.008±0.0002 |
Liver |
0.028±0.002 |
0.036±0.002 |
0.056±0.005 ** |
0.052±0.008 ** |
0.029±0.001 |
Adrenals |
0.00022±0.00006 |
0.00026±0.00004 |
0.00036±0.00004 ** |
0.00039±0.00006 ** |
0.00025±0.00004 |
Testes |
0.00027±0.00007 |
0.00029±0.00012 |
0.00025±0.00008 |
0.00027±0.00012 |
0.00026±0.00009 |
a Measurements on day 125, 2 of 10 and 3 of 6 rats excluded (due to death) in males and females, respectively
* P ≤0.05
** P≤0.01
Table 5. Incidence and Degree of Severity of Treatment-related Histopathological findings in the Kidney and Liver after a 90 day oral gavage study of C10-C13 dearomatised hydrocarbon solvent
Tissue/lesions |
Male (mg/kg/day) |
Female (mg/kg/day) |
||||||||
0 (veh) |
500 |
2500 |
5000 |
5000(Rec)a |
0 (veh) |
500 |
2500 |
5000 |
5000(Rec)a |
|
Liver |
||||||||||
No. examined |
10 |
10 |
10 |
10 |
8 |
10 |
10 |
10 |
14 |
3 |
No. normal |
3 |
4 |
4 |
2 |
2 |
4 |
4 |
1 |
2 |
1 |
Hypertrophy, hepatocellular, centrilobular |
||||||||||
Minimal |
0 |
3 |
4 |
1 |
0 |
0 |
3 |
5 |
6 |
0 |
Slight |
0 |
0 |
1 |
3 |
0 |
0 |
0 |
4 |
4 |
0 |
Kidneys |
||||||||||
No. examined |
10 |
10 |
10 |
10 |
8 |
10 |
10 |
10 |
14 |
3 |
Normal |
8 |
0 |
0 |
0 |
2 |
8 |
10 |
9 |
13 |
3 |
Basophilia, cortical tubules, multifocal |
||||||||||
Minimal |
1 |
3 |
3 |
2 |
2 |
0 |
0 |
0 |
1 |
0 |
Slight |
0 |
2 |
3 |
6 |
0 |
0 |
0 |
0 |
0 |
0 |
Moderate |
0 |
3 |
3 |
3 |
0 |
0 |
0 |
0 |
0 |
0 |
Dilated tubules/granular casts, medulla |
||||||||||
Minimal |
0 |
0 |
3 |
1 |
4 |
0 |
0 |
0 |
0 |
0 |
Slight |
0 |
0 |
1 |
4 |
0 |
0 |
0 |
0 |
0 |
0 |
Moderate |
0 |
3 |
3 |
3 |
0 |
0 |
0 |
0 |
0 |
0 |
Hyaline droplets, cortical tubules |
||||||||||
|
0 |
10 |
10 |
10 |
0 |
0 |
0 |
0 |
0 |
0 |
a2 male and 3 female recovery rats died prior to the 90 day necropsy. 4 female recovery rats were also transferred to the female high dose group
Table 6. Incidence and Degree of Severity of Treatment-related Gastritis and Peri-anal Irritation after a 90 day oral gavage study of C10-C13 dearomatised hydrocarbon solvent
Tissue/lesions |
Male (mg/kg/day) |
Female (mg/kg/day) |
||||||||
0 (veh) |
500 |
2500 |
5000 |
5000(Rec)a |
0 (veh) |
500 |
2500 |
5000 |
5000(Rec)a |
|
Stomach |
||||||||||
No. examined |
10 |
10 |
10 |
10 |
8 |
10 |
10 |
10 |
14 |
3 |
No. normal |
10 |
9 |
3 |
1 |
5 |
10 |
9 |
2 |
3 |
2 |
Edema/inflammation, sub mucosa |
||||||||||
Slight |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Moderate |
0 |
0 |
1 |
1 |
0 |
0 |
0 |
1 |
0 |
0 |
Hyperplasia/hyperkeratoasis, non-glandular mucosa |
||||||||||
Minimal |
0 |
0 |
4 |
0 |
2 |
0 |
0 |
6 |
0 |
0 |
Slight |
0 |
0 |
1 |
3 |
1 |
0 |
0 |
2 |
2 |
0 |
Moderate |
0 |
0 |
1 |
6 |
0 |
0 |
0 |
0 |
9 |
0 |
Marked |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Anus |
||||||||||
No. examined |
0 |
0 |
0 |
8 |
0 |
0 |
0 |
0 |
14 |
0 |
No. normal |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Hyperplasia/hyperkeratosis |
||||||||||
Slight |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
2 |
0 |
Moderate |
0 |
0 |
0 |
4 |
0 |
0 |
0 |
0 |
14 |
0 |
Infiltration, neutrophilic/pustules |
||||||||||
Minimal |
0 |
0 |
0 |
2 |
0 |
0 |
0 |
0 |
2 |
0 |
Slight |
0 |
0 |
0 |
2 |
0 |
0 |
0 |
0 |
9 |
0 |
Moderate |
0 |
0 |
0 |
3 |
0 |
0 |
0 |
0 |
3 |
0 |
Marked |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
Necrosis, mucosa |
||||||||||
Slight |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
Moderate |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
Marked |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
a2 male and 3 female recovery rats died prior to the 90 day necropsy. 4 female recovery rats were also transferred to the female high dose group
Table 7. Benchmark Dose Estimation of the Point of Departure for ALT Responses in Male Rats.
Model |
BMD (mg/kg) |
BMDL (mg/kg) |
GOFap-value |
AIC |
Scaled residual for dose group |
Default BMR (1SD) |
|||||
Exponential M4 |
271.174 |
163.321 |
0.2286 |
233.7707 |
-1.084 |
BMR – (adverse effect as 100% above concurrent control mean) |
|||||
Polynomial |
2588.94 |
1857.37 |
0.2902 |
233.439874 |
0.577 |
aGoodness of fit (p-value). The chosen model is considered as an acceptable model fit to the data when the p-value is greater than 0.1.
Microscopic changes in the male kidneys characterized by hyaline droplet accumulation in the cytoplasm of the proximal tubules of the cortex and an increased incidence of multi-focal cortical tubular basophila with changes consistent with both degeneration and regeneration of the tubular epithelium and dilated medullary tubules with granular casts are typical of a syndrome that occurs specifically in male rats and is unlikely to have a correlation to humans. The syndrome, Alpha-2u-Globulin Nephropathy or Light Hydrocarbon Nephropathy is related to the accumulation of alpha-2u globulin in the lysosomes of the kidney.
Treatment-related microscopic change in the liver (centrilobular hepatocellular hypertrophy) of the mid-dose females and the high dose of both sexes in the absence of necrosis is typical of an adaptive change probably related to the livers' metabolism of large volumes of test material. This observation is supported by the increase in relative liver weights in these animals which is typical of an adaptive change.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 500 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- 2 Key read across sub-chronic toxicity studies from structural analogues available for assessment. BMDL level determined and presented in the additional information section below.
Repeated dose toxicity: inhalation - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: inhalation
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- a short-term toxicity study does not need to be conducted because a reliable sub-chronic (90 days) or chronic toxicity study is available, conducted with an appropriate species, dosage, solvent and route of administration
- Endpoint:
- sub-chronic toxicity: inhalation
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- 1980
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Acceptable, well-documented study report equivalent or similar to OECD guideline 413.
- Justification for type of information:
- The justification for read across is provided as an attachment in IUCLID Section 13.
- Reason / purpose for cross-reference:
- read-across: supporting information
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 413 (Subchronic Inhalation Toxicity: 90-Day Study)
- GLP compliance:
- no
- Species:
- rat
- Strain:
- other: Albino
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Shell Toxicology Laboratory
- Age at study initiation: 10-13 weeks
- Fasting period before study:
- Housing: three of one sex/cage
- Diet (e.g. ad libitum): ad libitum, removed during exposure
- Water (e.g. ad libitum): ad libitum - Route of administration:
- inhalation: vapour
- Type of inhalation exposure:
- whole body
- Vehicle:
- other: unchanged (no vehicle)
- Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
The atmospheres were generated by completely evaporating the solvent into the streams of ventilating air entering the chambers using micro metering pumps and vaporizers. The vaporizers consisted of electronically heated quartz tubes.
- Exposure apparatus: aluminum with a volume of 1m3
- Source and rate of air: exhausted duct through which air was drawn by a fan situated on the roof of the laboratory
- Temperature, humidity, pressure in air chamber:
- Air flow rate: 1.8-2.0 m3/min
- Treatment of exhaust air: dust filters
TEST ATMOSPHERE
- Brief description of analytical method used: Analyzed continuously by means of a total hydrocarbon analyzer fitted with flame-ionization detectors.
- Samples taken from breathing zone: no - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Analyzed continuously by means of a total hydrocarbon analyzer fitted with flame-ionization detectors.
- Duration of treatment / exposure:
- 6h/day, 5days/week for 13 weeks
- Frequency of treatment:
- 6h/day, 5days/week for 13 weeks
- Remarks:
- Doses / Concentrations:
1500mg/m3
Basis:
nominal conc. - Remarks:
- Doses / Concentrations:
3000 mg/m3
Basis:
nominal conc. - Remarks:
- Doses / Concentrations:
6000mg/m3
Basis:
nominal conc. - No. of animals per sex per dose:
- 18 rats /sex/dose
- Control animals:
- yes
- Details on study design:
- The start and finish of the experiment was staggered in order that the optimum number of animals could be examined at necropsy after exposure. On each of 6 consecutive days, 3 male and 3 female rats per dose were started on the experiment. Thirteen weeks later, 3 male and 3 female rats per dose were removed from the experiment for pathological examination on each of 6 consecutive days.
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily
DETAILED CLINICAL OBSERVATIONS: Yes / No / No data
- Time schedule:
BODY WEIGHT: Yes
- Time schedule for examinations: weekly
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g/cage of 3 rats/week: Yes
WATER CONSUMPTION: Yes
- Time schedule for examinations: weekly
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: end of experiment
- Anaesthetic used for blood collection: No
- How many animals: all
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: end of experiment
- Animals fasted: No
- How many animals: all rats
URINALYSIS: Yes
control, low and high dose groups only
- Time schedule for collection of urine: following last exposure
NEUROBEHAVIOURAL EXAMINATION: Yes / No / No data
- Time schedule for examinations:
- Dose groups that were examined:
- Battery of functions tested: sensory activity / grip strength / motor activity / other:
- Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes - Statistics:
- Body and organ weights were analyzed by covariance analysis using the initial body weight as the covariate. Reported means were adjusted for initial body weight if a significant covariance relationship existed. Organ weights were further examined by covariance analysis using the terminal body weight as the covariate. The organ weight means were reported as adjusted for terminal body weight if a significant covariance relationship existed. Clinical chemical and hematological parameters were examined using analysis of variance. The significance of any difference between treated and control group means was tested using the Williams t-test. However, if a monotonic dose response could not be assumed, Dunnett’s test was used.
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- CLINICAL SIGNS AND MORTALITY
No deaths were recorded during the experiment and the general health of the animals remained good throughout the period of exposure.
BODY WEIGHT AND WEIGHT GAIN
No significant differences in male body weights due to exposure. Female body weights, however, were significantly reduced from control at the high dose.
FOOD CONSUMPTION
Female food intake showed and early significant reduction from control at the high exposure level.
WATER CONSUMPTION
Some significant increases were seen in both males and females at the highest dose.
HAEMATOLOGY
Significant decrease in male reticulocytes at the high dose, all other red and white cell parameters were normal
CLINICAL CHEMISTRY
Significant decrease in female ALT values at all exposure levels. Male chloride was significantly reduced at the medium and high dose levels and female beta protein was increased at the high level.
URINALYSIS
Glucose and protein were present in the urine of many of the rats, but animals were fed during collection period, therefore this is not unexpected. Very low incidence of exposed rats with glycosuria compared with control rats.
ORGAN WEIGHTS
Increase in male kidney weights at all exposure levels and an increase in male liver weights at the medium and high dose exposures. Female liver weights were also increased compared with controls at the high dose level. The differences were slightly enhanced when results were adjusted for terminal body weight.
GROSS PATHOLOGY
Increased incidence of renal pallor and subcapsular granularity in the male rats exposed to high concentrations. No other changes observed.
HISTOPATHOLOGY: NON-NEOPLASTIC
Kidneys of male rats exposed to all concentrations of BRIGHTSOL contained multiple, hyaline, intracytoplasmic, inclusion-droplets in the epithelium of the proximal convoluted tubules and showed an increased incidence of focal cortical, tubular basophilia.
A low grade catarrhal inflammatory reaction was evident in the nasal cavities of the majority of rats exposed to the medium concentration. The lesions were confined to the olfactory epithelium and comprised mild mucosal and submucosal edema, focal congestion and diffuse low grade inflammatory cell infiltrates. Unilateral and bilateral lesions occurred. - Key result
- Dose descriptor:
- NOAEC
- Effect level:
- >= 6 000 mg/m³ air (nominal)
- Sex:
- male/female
- Basis for effect level:
- other: No treatment-related mortality or significant adverse clinical effects occurred.
- Critical effects observed:
- not specified
- Conclusions:
- The NOAEC for BRIGHTSOL vapor following a 13-week inhalation exposure is greater than or equal to 6000mg/m3
- Executive summary:
BRIGHTSOL was administered by inhalation to albino rats for 6 hours/day, 5 days/week for 13 weeks at nominal vapor concentrations of 1500 mg/m3 and 3000 mg/m3, and 6000 mg/m3 to assess inhalation toxicity. No mortality or treatment-related effects in any of the hematology and serum chemistry values were observed. Liver and kidney weights were increased in male rats at all exposure levels, and liver weights were increased in female rats at 6000 mg/m3. In addition, the male rats exposed to BRIGHTSOL at all concentrations contained multiple, hyaline, intracytoplasmic, inclusion-droplets in the epithelium of the proximal convoluted tubules and showed an increased incidence of focal cortical, tubular basophilia. The kidney effects observed in male rats are indicative of alpha-2u-globulin nephropathy. Alpha-2u-globulin nephropathy, also known as hyaline droplet nephropathy, results from the formation of complexes with a naturally occurring protein (alpha-2u-globulin) in the kidneys of male rats. These complexes can accumulate in the proximal renal tubules and may produce species-specific histopathological changes. These kidney effects are specific to male rats and are not considered to be of biological relevance to humans. Histopathological examination did not reveal any abnormalities that were considered treatment related. As there were no pathologic changes, changes in liver weight to body weight ratios mentioned above were judged to have been compensatory rather than toxic effects. Based on these results, the No Observed Adverse Effect Concentration (NOAEC) was greater than or equal to 6000 mg/m3.
Referenceopen allclose all
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEC
- 6 000 mg/m³
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- 1 key read across sub-chronic toxicity study from a structural analogue available for assessment.
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: dermal
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- a short-term toxicity study does not need to be conducted because a reliable sub-chronic (90 days) or chronic toxicity study is available, conducted with an appropriate species, dosage, solvent and route of administration
- Endpoint:
- sub-chronic toxicity: dermal
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- other:
Referenceopen allclose all
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
There is no data available for repeated dose toxicity for Isohexadecane. However, data is available for structural analogues Hydrocarbons, C10-C13, n-alkanes, isoalkanes, cyclics, <2% aromatics and Hydrocarbons, C11-C14, n-alkanes, isoalkanes, cyclics, <2% aromatics and presented in the dossier. This data is read across to Isohexadecane based on analogue read across and a discussion and report on the read across strategy is provided as an attachment in IUCLID Section 13.
Oral:
Hydrocarbons, C10-C13, n-alkanes, isoalkanes, cyclics, <2% aromatics
In a key repeated dose oral toxicity study (ExxonMobil, 1991), the test material (Hydrocarbons, C10-C13, n-alkanes, isoalkanes, cyclics, <2% aromatics) was administered by oral gavage to rats at concentrations of 500, 2500 and 5000 mg/Kg, 7 days a week for 13 weeks to assess the subchronic toxicity. An additional group of animals, dosed at 5000 mg/Kg/day, was held for 4 weeks to assess reversibility. No treatment-related mortality was observed; however, male body weights were decreased while food consumption increased in the 2500 and 5000 mg/Kg dose groups. Liver weights were elevated in male and female rats at 2500 and 5000 mg/Kg/day. Adrenal weights were significantly increased in male and female rats at 5000 mg/kg and in female rats at 2500 and 5000 mg/Kg. Testes weights were elevated in male rats at 5000 mg/Kg. Kidney effects occurred in males at all dose levels, and are indicative of alpha-2u-globulin nephropathy. Alpha-2u-globulin nephropathy, also known as hyaline droplet nephropathy, results from the formation of complexes with a naturally occurring protein (alpha-2u-globulin) in the kidneys of male rats. These complexes can accumulate in the proximal renal tubule and may produce species-specific histopathological changes. These kidney effects are specific to male rats and are not considered to be of biological relevance to humans.
Dose-related changes in hematology or serum chemistry parameters were observed and were consistent with the changes seen in the liver. Histological findings of hepatocellular hypertrophy (liver cell enlargement) were seen in livers of both sexes in all dose groups. These findings are believed to have been a compensatory response and not an indication of toxicity. Additionally, these liver effects were reversible and occurred only at high doses that are not typical of hydrocarbon exposures for humans. Other treatment-related effects were mucosal thickening and other signs of irritation of the stomach and anus which appear to be the direct result of high dose intubation of a the locally irritating test substance. These effects are believed to have been a compensatory response to local irritation and not an indication of toxicity. All treatment-related effects were reversible within the 4-week recovery period. Based on a significant increase in ALT levels in the 2500 and 5000 mg/kg/day treatment groups in male rats, the No Observed Adverse Effect Level (NOAEL) for the 90-day study was greater than 500 mg/Kg/day.
This NOAEL value is dependent on doses selected in the study and may not represent a true biological threshold. In order to circumvent the problem of dose-selection bias, benchmark analysis was used to determine a benchmark dose for this study, using individual ALT dose–response values in male rats as the critical effect. Since the minimal level of change in the endpoint (increased serum ALT) that would be considered biologically significant was known (2–4-fold increase compared to concurrent control values), this value was used as the Benchmark response in the derivation of a BMDL, although the BMDL value using the EPA default BMR of 1SD from the mean was provided for comparison. The use of the 1SD default for the BMR resulted in an overly conservative BMDL value, 3-fold lower than would have been predicted using the NOAEL/ LOAEL approach. When the BMR was more accurately defined in terms of a 2-fold minimum level of change over the control mean, the estimated BMDL value was 1857 mg/Kg/day.
Hydrocarbons, C11-C14, n-alkanes, isoalkanes, cyclics, <2% aromatics
In another key 90-day sub-chronic study (ExxonMobil, 1991) conducted in rats the test material (Hydrocarbons, C11-C14, n-alkanes, isoalkanes, cyclics, <2% aromatics) was administered by oral gavage at a dose of 0, 100, 500, or 1000 mg/Kg 7 days per week for a period of 13 weeks. The control animals received a carrier (corn oil) dose and a satellite group was dosed at 1000 mg/Kg, 7 days/week for 13 weeks and was then observed for reversibility, persistence or delayed occurrence of toxic effects for 28 days post-treatment. Observations were made as to the nature, onset, severity, and duration of toxicological signs. There were no deaths attributed to the oral administration of the test material (two control group females died prior to termination). The majority of animals in all groups displayed no observable abnormalities during the test period. The most frequently noted observations included broken/maloccluded incisors, alopecia, and scabs, all of which were considered incidental. Body weight, food consumption, and hematology data displayed no biologically significant trends for either males or females during the test period. The most remarkable finding was a treatment-related microscopic change in the liver of the mid-dose females and the high dose of both sexes. This change was minor and is typical of an adaptive change probably related to the livers metabolism of large volumes of test material and was reversible upon microscopic evaluation of the tissues from the satellite recovery group. Microscopic changes were also observed in the male kidneys at all doses. These changes are characteristic of kidney changes produced in male rats by hydrocarbons and are considered to be a male rat specific phenomenon without human significance. Based on the data recorded in this study, the NOAEL for hydrocarbons, C11-C14, n-alkanes, isoalkanes, cyclics, <2% aromatics is >1000mg/Kg.
Additionally, OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents) tests are proposed for Isohexadecane and structural analogue hexadecane. This data is read across to based on analogue read across and a discussion and report on the read across strategy is provided as an attachment in IUCLID Section 13.This endpoint will be updated subsequent to ECHA's approval of the testing proposals and availability of data upon completion of the studies.
Inhalation:
Hydrocarbons, C11 -C14, n-alkanes, isoalkanes, cyclics, <2% aromatics
BRIGHTSOL was administered by inhalation to albino rats for 6 hours/day, 5 days/week for 13 weeks at nominal vapor concentrations of 1500 mg/m3and 3000 mg/m3, and 6000 mg/m3to assess inhalation toxicity. No mortality or treatment-related effects in any of the hematology and serum chemistry values were observed (Shell, 1980). Liver and kidney weights were increased in male rats at all exposure levels, and liver weights were increased in female rats at 6000 mg/m3. In addition, the male rats exposed to BRIGHTSOL at all concentrations contained multiple, hyaline, intracytoplasmic, inclusion-droplets in the epithelium of the proximal convoluted tubules and showed an increased incidence of focal cortical, tubular basophilia. The kidney effects observed in male rats are indicative of alpha-2u-globulin nephropathy. Alpha-2u-globulin nephropathy, also known as hyaline droplet nephropathy, results from the formation of complexes with a naturally occurring protein (alpha-2u-globulin) in the kidneys of male rats. These complexes can accumulate in the proximal renal tubules and may produce species-specific histopathological changes. These kidney effects are specific to male rats and are not considered to be of biological relevance to humans. Histopathological examination did not reveal any abnormalities that were considered treatment related. As there were no pathologic changes, changes in liver weight to body weight ratios mentioned above were judged to have been compensatory rather than toxic effects. Based on these results, the No Observed Adverse Effect Concentration (NOAEC) was greater than or equal to 6000 mg/m3.
Justification for classification or non-classification
Based on the available read across data, Isohexadecane does not meet the criteria for classification for repeated dose toxicity (STOT-RE) under the new Regulation (EC) 1272/2008 on classification, labeling and packaging of substances and mixtures (CLP).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.